603392.SH
万泰生物
SSE · Healthcare · Biotechnology · CN
CNY 28.09
−8.17%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.9B | 1.8B | 2.2B | 5.5B | 11.2B |
| Cost of Revenue | 945.6M | 921.8M | 759.0M | 873.2M | 1.2B |
| Gross Profit | 996.1M | 897.1M | 1.5B | 4.6B | 10.0B |
| Operating Expenses | |||||
| R&D Expense | 532.0M | 560.8M | 886.1M | 1.2B | 1.1B |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 386.3M | 384.0M | 347.1M | 352.6M | 234.9M |
| Selling & Marketing Expense | 486.9M | 445.7M | 438.4M | 1.5B | 3.3B |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 1.4B | 1.4B | 1.6B | 3.0B | 4.6B |
| Cost and Expenses | 2.4B | 2.3B | 2.4B | 3.9B | 5.7B |
| Operating Income (EBIT) | (472.1M) | (469.2M) | 93.8M | 1.4B | 5.6B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (482.9M) | (480.9M) | 67.5M | 1.4B | 5.6B |
| Income Tax Expense | (78.1M) | (66.9M) | (41.6M) | 146.9M | 719.4M |
| Bottom Line | |||||
| Net Income | (388.5M) | (398.3M) | 106.2M | 1.2B | 4.7B |
| Earnings from Cont. Ops | (404.7M) | (414.0M) | 109.1M | 1.2B | 4.9B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (388.5M) | (398.3M) | 106.2M | 1.2B | 4.7B |
| Per Share | |||||
| Basic EPS | (CN¥0.30) | (CN¥0.31) | CN¥0.08 | CN¥0.99 | CN¥3.79 |
| Diluted EPS | (CN¥0.30) | (CN¥0.31) | CN¥0.08 | CN¥0.99 | CN¥3.79 |
| Revenue Per Share | CN¥1.36 | CN¥1.42 | CN¥1.69 | CN¥4.37 | CN¥8.95 |
| Shares | |||||
| Basic Shares Outstanding | 1.4B | 1.3B | 1.3B | 1.3B | 1.2B |
| Diluted Shares Outstanding | 1.4B | 1.3B | 1.3B | 1.3B | 1.2B |
| Profitability Metrics | |||||
| EBITDA | — | (131.4M) | 372.1M | 1.6B | 5.7B |
| D&A | — | 337.8M | 278.3M | 239.4M | 142.8M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026